相关实验视频
Updated: Jul 5, 2026

10:33
Generation of Alginate Microspheres for Biomedical Applications
Published on: August 12, 2012
20.9K
维鲁布林 (Azixa) 类似物与增加和:合成,SAR和封装在生物相容纳米容器基于Ca2+或Mg2+交联酸
Kseniya N Sedenkova1, Denis N Leschukov1, Yuri K Grishin1
1Department of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Pharmaceuticals (Basel, Switzerland)
|October 28, 2023
概括
新的针对图林聚合的维鲁布林类似物显示出强大的抗癌活性,对癌细胞系具有显著的细胞毒性. 纳米容器中的封装保留了化合物的疗效.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 纳米技术纳米技术
背景情况:
- 芽素向剂在抗癌药物开发中至关重要.
- 维鲁布林是一种已知的氨酸聚合抑制剂,它结合于菌素结合部位.
研究的目的:
- 为了合成和评估抗癌性质的新型维鲁布林类似物.
- 研究这些类似物对各种癌症和非癌症细胞系的细胞毒性.
- 评估纳米载体系统提供化合物的潜力.
主要方法:
- 合成含有化环合或环合环的维鲁布林类似物与金胺.
- 在癌症和非癌症细胞系上进行细胞毒性测试 (MTT测试).
- 光显微镜观察细胞骨破坏.
- 击中化合物的封装在Ca2+/Mg2+交联的酸盐纳米容器中.
主要成果:
- 合成的类似物显示出对癌细胞系的强有力的细胞毒性,IC50值低至1-4nM.
- 细胞毒性化合物诱导了异常的细胞骨破坏,类似于combretastatin A-4.
- 在酸盐纳米容器中封装后,化合物的细胞毒性活性保持.
结论:
- 新的维鲁布林类似物通过抑制氨酸聚合,显示出显著的抗癌潜力.
- 化合物是进一步开发的有希望的候选者,通过纳米容器可以进行增强的交付.
相关概念视频
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

